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RESEARCH
Effectiveness and safety of non-steroidal anti-inflammatory 
drugs and opioid treatment for knee and hip osteoarthritis: 
 network meta-analysis
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ABSTRACT
OBJECTIVE
To assess the effectiveness and safety of different 
preparations and doses of non-steroidal anti-
inflammatory drugs (NSAIDs), opioids, and 
paracetamol for knee and hip osteoarthritis pain and 
physical function to enable effective and safe use of 
these drugs at their lowest possible dose.
DESIGN
Systematic review and network meta-analysis of 
randomised trials.
DATA SOURCES
Cochrane Central Register of Controlled Trials (CENTRAL), 
Medline, Embase, regulatory agency websites, and 
ClinicalTrials.gov from inception to 28 June 2021.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised trials published in English with ≥100 
patients per group that evaluated NSAIDs, opioids, or 
paracetamol (acetaminophen) to treat osteoarthritis.
OUTCOMES AND MEASURES
The prespecified primary outcome was pain. Physical 
function and safety outcomes were also assessed.
REVIEW METHODS
Two reviewers independently extracted outcomes 
data and evaluated the risk of bias of included trials. 
Bayesian random effects models were used for 
network meta-analysis of all analyses. Effect estimates 
are comparisons between active treatments and oral 
placebo.
RESULTS
192 trials comprising 102 829 participants examined 
90 different active preparations or doses (68 for 
NSAIDs, 19 for opioids, and three for paracetamol). 
Five oral preparations (diclofenac 150 mg/day, 
etoricoxib 60 and 90 mg/day, and rofecoxib 25 and 50 
mg/day) had ≥99% probability of more pronounced 
treatment effects than the minimal clinically relevant 
reduction in pain. Topical diclofenac (70-81 and 
140-160 mg/day) had ≥92.3% probability, and all 
opioids had ≤53% probability of more pronounced 
treatment effects than the minimal clinically relevant 
reduction in pain. 18.5%, 0%, and 83.3% of the oral 
NSAIDs, topical NSAIDs, and opioids, respectively, 
had an increased risk of dropouts due to adverse 
events. 29.8%, 0%, and 89.5% of oral NSAIDs, topical 
NSAIDs, and opioids, respectively, had an increased 
risk of any adverse event. Oxymorphone 80 mg/day 
had the highest risk of dropouts due to adverse events 
(51%) and any adverse event (88%).
CONCLUSIONS
Etoricoxib 60 mg/day and diclofenac 150 mg/day 
seem to be the most effective oral NSAIDs for pain 
and function in patients with osteoarthritis. However, 
these treatments are probably not appropriate for 
patients with comorbidities or for long term use 
because of the slight increase in the risk of adverse 
events. Additionally, an increased risk of dropping out 
due to adverse events was found for diclofenac 150 
mg/day. Topical diclofenac 70-81 mg/day seems to 
be effective and generally safer because of reduced 
systemic exposure and lower dose, and should be 
considered as first line pharmacological treatment 
for knee osteoarthritis. The clinical benefit of opioid 
treatment, regardless of preparation or dose, does 





Osteoarthritis is a clinical syndrome that most 
commonly affects knee and hip joints in older people.1 
Osteoarthritis is a painful condition and results in 
reduced physical function and quality of life, and 
increased risk of all cause mortality.2-4 Topical or 
oral non-steroidal anti-inflammatory drugs (NSAIDs) 
followed by paracetamol (acetaminophen) or opioids 
comprise first line pharmacotherapy.5-7 In the United 
States, 65% of patients with osteoarthritis are pre-
scribed NSAIDs and 71% opioids for pain management, 
and opioid prescriptions for musculoskeletal pain 
For numbered affiliations see 
end of the article
Correspondence to: B R da Costa  
bruno.dacosta@utoronto.ca 
(ORCID 0000-0002-1786-6332)
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2021;375:n2321 
http://dx.doi.org/10.1136/bmj.n2321
Accepted: 13 September 2021
WHAT IS ALREADY KNOWN ON THIS TOPIC
Previous systematic reviews have reported on the effectiveness of non-steroidal 
anti-inflammatory drugs (NSAIDs) and opioids to treat osteoarthritis pain
These reviews clustered drug doses or drug classes in their analyses
WHAT THIS STUDY ADDS
Etoricoxib 60 mg/day and diclofenac 150 mg/day seem to be the most effective 
oral NSAIDs for knee and hip osteoarthritis pain and physical function, but might 
not be appropriate in the presence of comorbidities or for long term use
Topical diclofenac 70-81 mg/day could be effective and generally safer because 
of reduced systemic exposure and lower dose, and should be considered as first 
line pharmacological treatment for knee osteoarthritis
The clinical benefit of opioid treatment, regardless of preparation or dose, does 
not outweigh the harm it might cause in patients with osteoarthritis
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increased by 70% between 2001 and 2010.8 In the 
UK, 84% of all patients diagnosed with osteoarthritis 
between 2000 and 2015 were prescribed opioids, with 
increasing numbers of prescriptions and prescribed 
doses in more recent years.9
Clinicians are faced with a myriad of options when 
prescribing pharmacotherapy, posing a challenge 
to clinical decision making. Evidence suggests that 
improvements in pain and physical function could 
be similar for opioids and NSAIDs, but opioids cause 
considerably more adverse events.10 11 Seven of the 
10 recommendations made in a recent guideline 
for opioid treatment in chronic non-cancer pain are 
focused on harm reduction12 because of a substantial 
risk associated with opioid use.13 In addition to the 
immediate reactions after opioid use, such as nausea, 
vomiting, and drowsiness,14 chronic use is associated 
with increased risk of fractures, cardiovascular 
events, opioid dependence, and mortality.15 Globally, 
opioid use disorder increased 23% between 2005 and 
2015.16 Over half of all global overdose deaths in 2019 
occurred in the US, with liberal prescribing of high 
dose opioids one of the main contributors.17 Between 
2000 and 2017, opioid related mortality increased 
by 593% in Canada.18 Despite this evidence, and 
international concerns about the devastating potential 
for chemical dependency,7 19 opioids remain among 
the most prescribed drugs for osteoarthritis pain in 
the UK, the US, Canada, and Australia, even though 
safer treatments with stronger analgesic effects are 
available.9 20-23
Previous systematic reviews have reported 
the effectiveness of NSAIDs and opioids to treat 
osteoarthritis pain.24-28 However, these reviews 
clustered drug doses or drug classes in their analyses. 
This clustering does not provide enough granular 
evidence to allow the implementation of current 
recommendations that physicians should prescribe the 
lowest while still effective dose of these interventions.6 
7 To present granular evidence and enable a safer 
prescription of these interventions, we assessed the 
effectiveness and safety of different preparations and 
doses of NSAIDs, opioids, and paracetamol for knee 
and hip osteoarthritis pain and physical function. We 
integrated all available high quality evidence from 
randomised trials in a network meta-analysis.
Methods
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-analyses (PRISMA) guidelines to 
prepare this article (see web-appendix 1 for protocol; 
PROSPERO registration CRD42020213656).
Eligibility criteria
We considered large randomised trials of patients with 
knee or hip osteoarthritis that compared any of the 
following interventions for pharmacological treatment 
of osteoarthritis pain: NSAIDs, opioids, paracetamol 
(acetaminophen), or placebo. Trials that included 
patients with other types of arthritis or joints other than 
knee or hip were only included if ≥75% of the patients 
had confirmed knee or hip osteoarthritis. Additionally, 
trials were required to have at least one follow-up 
measurement of pain or another algofunctional 
outcome. To reduce small study bias, we only included 
trials with an average of ≥100 participants randomised 
per arm.29 No publication status or year restriction was 
applied, but we limited the publication language to 
English.
Identification of trials
To identify eligible trials, we conducted searches on 
the Cochrane Central Register of Controlled Trials 
(CENTRAL), from inception to 30 June 2021, and 
Medline and Embase from inception to 28 June 2021 
(web-appendix 2). We also manually searched the 
reference lists of retrieved articles and systematic 
reviews (web-appendix 3), and searched ClinicalTrials.
gov. When data were incomplete, we searched for 
additional data on ClinicalTrials.gov, WHO approved 
trial registries, company specific trial registries, and 
documents available on the website of the US Food and 
Drug Administration (FDA).
Selection of studies and data extraction
Each trial was independently evaluated by two 
reviewers (BRdC, CAH, HDK, LG, MOA, MR, NSB, PB, 
PSC, PS, RH, SMI, TM, and TVP) for screening and data 
extraction. When disagreements occurred, a consensus 
was reached through discussion among reviewers or by 
consultation with a senior scholar. We screened trials 
for eligibility, extracted data, and developed consensus 
by using a standardised and piloted web based data 
management tool, accompanied by a codebook. We 
extracted trial characteristics, such as design, size and 
duration; intervention characteristics, such as dose 
and treatment duration; participant characteristics, 
such as mean age, sex, mean duration of symptoms, 
index joint; type of outcome (pain or function); 
and outcome data for each time point of interest. If 
necessary, we approximated summary statistics and 
measures of variability from graphs. When possible, 
results based on the intention-to-treat principle were 
extracted.
Outcomes
Our prespecified primary outcome was pain. If a trial 
presented pain outcomes on more than one scale, 
the following hierarchical list was used to extract 
data from the scale highest on the list30 31: (1) global 
osteoarthritis pain assessed using visual analogue 
or numerical rating scales; (2) pain on walking; 
(3) Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) pain subscore; (4) 
composite pain scores other than WOMAC; (5) 
pain on activities other than walking (such as stair 
climbing); (6) WOMAC global score; (7) Lequesne 
osteoarthritis index score; (8) other algofunctional 
composite scores; (9) patient’s global assessment; 
(10) physician’s global assessment. Data were 
extracted for several time points when available: 1 
week (±2 days), 2 weeks (±2 days), 4 weeks (3-4.5 
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weeks), 6 weeks (±1 week), 12 weeks (±4 weeks), 24 
weeks (±4 weeks), 48 weeks (±4 weeks), and at the 
end of treatment if not covered by the specific time 
points. The extraction of several time points allowed 
us to conduct advanced modelling to achieve more 
statistical precision. However, we only present results 
at six weeks (primary analysis), and one and 12 
weeks (sensitivity analyses).
Our secondary outcome was physical function. If 
a trial presented function outcomes on more than 
one scale, the following hierarchical list was used 
to extract data from the scale highest on the list30: 
(1) global osteoarthritis function score; (2) walking 
disability; (3) WOMAC physical function subscore; 
(4) composite physical function scores other than 
WOMAC; (5) physical function on activities other than 
walking (such as stair climbing); (6) WOMAC global 
score; (7) Lequesne osteoarthritis index score; (8) 
other algofunctional composite scores; (9) patient’s 
global assessment; (10) physician’s global assessment. 
We extracted and analysed data on this outcome for 
the same time points as those described for pain.
Our main safety outcome was dropouts or 
withdrawals due to adverse events. Other safety 
outcomes were any adverse event and serious adverse 
events. We extracted serious adverse events as defined 
by investigators. This outcome was typically defined as 
those resulting in hospital admission, prolongation of 
hospital stay, persistent or major disability, congenital 
abnormality of offspring, life threatening events, or 
death.32
Risk of bias assessment
We judged trial risk of bias for seven domains: random 
sequence generation, allocation concealment, 
blinding of patients, blinding of the therapist, blinding 
of outcome assessor for pain, blinding of outcome 
assessor for function, and completeness of outcome 
data (web-appendix 4).33-35
Statistical methods
For the analysis of pain and physical function out-
comes, we used an extension of multivariable Bayesian 
random effects models for network meta-analysis 
(web-appendix 5).33 36 37 These models fully preserve 
the direct randomised comparison within each trial, 
but allow the comparison of all available interventions 
across trials, and account for multiple comparisons 
in multiarm trials.38 39 The model includes random 
effects at the level of trials, and uses a random walk 
to account for the correlation of longitudinal outcome 
data within trials reporting results for more than one 
time point, borrowing strength across time points for 
an estimate. The model assumes that, within a trial 
with longitudinal outcome data, the data recorded at 
a specified time point are more similar to the outcome 
data recorded at adjacent time points immediately 
before and after than at non-adjacent, more remote 
time points.40 Pain and physical function treatment 
effects are presented as standardised mean differences. 
We present the results for six week follow-up for all 
analyses, and a sensitivity analysis was conducted for 
one and 12 week follow-up.
We also adjusted the results of the primary outcome 
for trial characteristics (concealment of allocation, 
blinding of patient, therapist, or outcome assessor, 
completeness of outcome data) by incorporating a 
regression coefficient in the model. We estimated 
two sided P values for interaction between treatment 
effects and trial characteristics from the posterior 
distribution. We assessed potential dose-response 
relations by introducing preparation specific 
covariates and assuming linearity on log relative dose 
in a separate model.33 We used different assumptions 
about the prior distribution of between trial variance 
to assess the robustness of our analysis (web-appendix 
1). To analyse safety outcomes, we calculated odds 
ratios by using a random effects network meta-analysis 
Bayesian model with binomial likelihood and logit 
link.41
For all variables, minimally informative prior 
distributions were used (web-appendix 1).33 All 
estimates reported are medians with corresponding 
95% credible intervals from the 2.5th and 97.5th 
percentiles of the posterior distribution, unless stated 
otherwise. We calculated effect sizes within trials 
by dividing the difference in mean values between 
treatment groups at a specific time point by the 
median pooled standard deviation recorded across 
all time points.42 If standard deviations were not 
provided, we calculated them from standard errors 
or confidence intervals,43 44 or imputed them using a 
regression based model if required (web-appendix 6). 
We assessed the goodness of fit of the model to the data 
by calculating the number of means of standardised 
residuals that were within 1.96 of the standard normal 
distribution at the level of interventions (node level); 
visually inspecting the distribution of residuals on 
Q-Q plots; comparing the posterior mean residual 
deviance with the number of data points; calculating 
the heterogeneity of treatment effects estimated from 
the posterior median between trial variance45 τ2; and 
assessing the consistency of the network (determined 
by the difference in effect sizes derived from direct and 
indirect comparisons).46 Consistency was assessed 
by using a stepwise approach.47 We first compared 
the model fit of consistency and inconsistency 
models using the deviance information criterion 
for an omnibus assessment of consistency.47 If the 
inconsistency model had a better deviance information 
criterion than the consistency model, we would then 
use node splitting to identify inconsistent loops within 
the network.47 Model convergence was assessed with 
the Brooks-Gelman-Rubin diagnostic, trace plots, and 
autocorrelation plots.
We estimated the probability for the effect of the 
experimental intervention to reach the between 
group minimum clinically important difference (MID) 
of −0.37 standard deviation units to facilitate the 
interpretation of estimated treatment effects.35 This 
threshold of 0.37 standard deviation units is based 
on the median between group anchor based MID 
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reported in studies in patients with osteoarthritis.35 
An effect size of 0.37 corresponds to a between group 
difference of 9 mm on a 100 mm visual analogue 
scale. We conducted a random effects meta-analysis to 
calculate the pooled probability of dropping out due to 
an adverse event in the oral placebo group, which was 
5%. The logit of this probability and the log odds ratios 
of comparisons to oral placebo were used to derive the 
probability of dropping out due to an adverse event for 
all other interventions. Analyses were done with Stata 
15.1 (StataCorp, TX, USA), OpenBUGS (OpenBUGS 
Project Management Group, version 3.2.3), and R 
version 3.6.1.48
Patient and public involvement
Patients and the public were not involved in the 
design, conduct, reporting, or dissemination plans of 
this systematic review and network meta-analysis due 
to lack of resources to allow their participation.
Results
Search results and characteristics of included trials
We screened 21 713 references of which 153 were 
found to be eligible (fig 1). Twenty eight additional 
trials were identified from the reference lists of relevant 
papers and in ClinicalTrials.gov. In total, we included 
data from 181 publications describing 192 trials. These 
trials involved 102 829 participants with a median 
sample size of 466 participants (interquartile range 
309-718). Considering different drug preparations 
and doses, a total of 90 active intervention nodes 
(hereafter referred to as interventions) were examined 
for at least one of the outcomes of interest: 68 NSAIDs, 
19 opioids, three paracetamol (table 1, table 2, table 
3, and web-appendix 7 and 8). Additionally, three 
control interventions were included in the network: 
oral, topical, and oral plus topical placebo. Celecoxib 
200 mg/day was the most frequently investigated 
intervention (44 trials). Only safety data were 
available for nine interventions (web-appendix 7). 
Web-appendix 9 shows the network of interventions 
included in the pain outcome analysis.
The mean age of participants in included trials 
ranged from 48 to 72 years, the percentage of female 
participants ranged from 13% to 91%, the median 
average time since osteoarthritis diagnosis was 
6.6 years (interquartile range 5.3-8.6), the median 
average baseline pain on a 10 cm scale was 6.5 
(interquartile range 5.7-7.0), and the median total 
follow-up was 8.6 weeks (interquartile range 6-12 
weeks; table 1 and web-appendix 10). Web-appendix 
11 shows the characteristics of each individual trial: 
91% of trials had a low risk of bias for blinding of 
patients, 83% for blinding of therapists, 91% for 
blinding of pain outcome assessor, 93% for blinding 
of function outcome assessor, 25% for incomplete 
pain outcome data, 26% for incomplete function 
outcome data, and 15% for allocation concealment 
(web-appendix 12). Eighty per cent of trials received 
financial funding from a commercial body and the 
source of funding was unclear in 19%.
Pain
Table 2, table 3, and web-appendix 7 present pooled 
effect estimates with 95% credible intervals for 
comparisons to oral placebo for all outcomes. Figure 
2 and figure 3 display pooled effect estimates for pain, 
ordered by the magnitude of treatment effects: 38 of 51 
(74.5%) oral NSAIDs, 3 of 9 (33.3%) topical NSAIDs, 4 
of 18 (22.2%) opioids, and 1 of 3 (33.3%) paracetamol 
interventions showed statistical superiority over oral 
placebo. For seven comparisons, all of which were 
NSAIDs (aceclofenac 200 mg/day, diclofenac 150 mg/
day, etoricoxib 60 and 90 mg/day, rofecoxib 25 and 
50 mg/day, and diclofenac topical 140-160 mg/day), 
we found robust statistical evidence for treatment 
effects that were more pronounced than the MID 
(the probability that the effect size compared with 
oral placebo is −0.37 or lower was ≥95%). Of these 
comparisons, five (diclofenac 150 mg/day, etoricoxib 
60 and 90 mg/day, and rofecoxib 25 and 50 mg/day) 
had ≥99% probability.
Topical diclofenac was the most promising topical 
treatment with ≥92.3% probability of more pronounced 
treatment effects than the MID, regardless of dose. 
Although some evidence was found of small treatment 
effects for opioids, all had ≤53.0% probability of 
treatment effects being more pronounced than the 
MID. Estimates in table 2 and table 3 indicate that, for 
some interventions, treatment effect increased with 
increasing treatment dose. However, there was generally 
a wide overlap of 95% credible intervals across doses of 
the same preparation, with only celecoxib, etoricoxib, 
naproxcinod, and tramadol having a significant dose 
dependency (P≤0.04; web-appendix 13). However, 
neither celecoxib nor tramadol had a high probability 
of treatment effect being more pronounced than the 
MID (≤24.7% and ≤18.1%, respectively). Results shown 
in web-appendix 14 indicate that treatment effects are 
generally similar from one week to 12 weeks of follow-
up. No strong evidence was found that risk of bias 
indicators influenced trial results in a systematic way 
(all P for interaction values ≥0.13; web-appendix 15). 
Results were much the same regardless of the prior 
distribution assumed for the between trial variance 
(web-appendix 16).
Physical function
For physical function, pooled estimates indicate that 
all interventions improved function compared with oral 
placebo except for two: nabumetone 1000 mg/day and 
paracetamol <2000 mg/day (web-appendix 7). Thirty of 
39 (76.9%) oral NSAIDs, 3 of 9 (33.3%) topical NSAIDs, 
4 of 13 (30.8%) opioids, and 1 of 3 (33.3%) paracetamol 
interventions showed statistical superiority over 
oral placebo. For two comparisons with oral placebo 
(rofecoxib 25 mg/day and naproxcinod 1500 mg/day), 
the upper bound of the 95% credible interval excluded 
treatment effects that were above the MID of −0.37.
Safety
Web-appendix 7 presents the results from the analysis 
of dropouts due to adverse events, any adverse event, 
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Records identified through screening of references
of included trials and previous systematic reviews
Publications excluded
Correlated reports from included trials
Insufficient data available
Language of publication other than English
RCT with less than 100 patients per arm (on average)
Condition other than knee or hip osteoarthritis
No RCT or other type of clinical or laboratory studies
Study protocol only
Full text could not be retrieved
Duplicates
Editorials. commentaries, or reviews














Condition other than knee or hip osteoarthritis
RCT with less than 100 patients per arm (on average)
Surgery related treatments
No RCT – other type of clinical or laboratory studies
Postoperative pain or post-surgery related outcome
Duplicates
Editorials, commentaries, or reviews
Intervention not relevant
Other reasons: no relevant outcome, osteoarthritis
  type not described, health economic evaluation,
  proportion of patients with knee or hip osteoarthritis
  unclear, less than 75% of patients with knee or hip











Full text assessed for eligibility
Records identified through
electronic database searching






















NSAIDs v opioids (1.0)
5
2
NSAIDs v acetaminophen (4.7)9
Three active interventions with the same dose,
Control group treated with drug class other than NSAIDs, opioids or acetaminophen
Interventions not connected to the network
Fig 1 | Study selection
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Table 1 | Characteristics of randomised trials included in systematic review and network meta-analysis
    Characteristics Number (%)
    Drugs
    Oral NSAIDs 288 (55.5)
    Topical NSAIDs 32 (6.2)
    Opioids 53 (10.2)
    Paracetamol 16 (3.1)
    Placebo 130 (25)
    Type of control
    Placebo 130 (67.7)
    Active intervention 62 (32.3)
    Average age (years)
    <55 10 (5.2)
    55-59.9 31 (16.1)
    60-64.9 123 (64.1)
    65-69.9 17 (8.9)
    ≥70 6 (3.1)
    Not reported 5 (2.6)
    Average body mass index
    <25 2 (4.2)
    25-30 14 (29.2)
    >30 32 (66.7)
    Average baseline pain on 10 cm scale, median (IQR) 6.5 (5.7-7.0)
    Average disease duration (years)
    <5 17 (20.2)
    5-10 61 (72.6)
    >10 6 (7.1)
    Average % of women
    <50 9 (4.7)
    50-59 31 (16.1)
    60-69 91 (47.4)
    ≥70 58 (30.2)
    Not reported 3 (1.6)
    Publication status
    Published 177 (92.2)
    Unpublished 15 (7.8)
    Year of publication
    1982-89 12 (6.3)
    1990-99 33 (17.2)
    2000-09 89 (46.4)
    2010-21 58 (30.2)
    Sample size (No of participants)
    200-250 31 (16.1)
    251-500 73 (38)
    501-1000 63 (32.8)
    >1000 25 (13)
    Follow-up duration (weeks)
    <12 96 (50)
    12-24 73 (38)
    24-48 12 (6.3)
    >48 11 (5.7)
    No of arms
    2 86 (44.8)
    3 60 (31.3)
    4 28 (14.6)
    ≥5 18 (9.4)
    Industry funding
    Yes 153 (79.7)
    Unclear 37 (19.3)
    No 2 (1)
    Deterministic imputation of missing data
    Yes 103 (53.6)
    Unclear 79 (41.1)
    No 10 (5.2)
    Centre
    Multicentre 181 (94.3)
    Single centre 2 (1)
    Unclear 9 (4.7)
NSAID=non-steroidal anti-inflammatory drug.
All variables are presented at trial level, except for drugs, which are presented at level of randomised treatment arms. Information on body mass index 
and disease duration was reported in <50% of the trials. For unpublished reports, publication date was date study data were made available online or 
date reported in official files or regulatory documents. Examples of deterministic methods of imputation include last observation carried forward, baseline 
observation carried forward, mean imputation. 
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NSAIDs
Pain Dropouts due to adverse 
events, odds ratio (95% Crl)Effect size (95% Crl) Probability of MID
Oral
Aceclofenac 200 mg* −0.56 (−0.78 to −0.34) 95.1 1.42 (0.92 to 2.21)
Celecoxib 100 mg −0.10 (−0.26 to 0.06) 0.0 0.83 (0.52 to 1.34)
Celecoxib 200 mg −0.35 (−0.40 to −0.30) 20.0 1.04 (0.90 to 1.21)
Celecoxib 400 mg* −0.32 (−0.47 to −0.16) 24.7 1.08 (0.70 to 1.67)
Diclofenac ≤75 mg −0.42 (−0.65 to −0.18) 65.1 2.64 (1.53 to 4.65)
Diclofenac 100-105 mg −0.47 (−0.63 to −0.31) 88.4 1.48 (1.12 to 1.97)
Diclofenac 114-133 mg −0.64 (−1.40 to 0.11) 75.9 1.79 (0.74 to 4.42)
Diclofenac 150 mg* −0.56 (−0.68 to −0.45) 99.9 1.67 (1.31 to 2.13)
Diflunisal 750 mg −0.33 (−0.69 to 0.03) 41.2 0.94 (0.35 to 2.50)
Diflunisal 1000 mg −0.40 (−0.77 to −0.04) 57.0 1.97 (0.83 to 4.79)
Etodolac 600 mg −0.57 (−0.83 to −0.31) 93.1 1.22 (0.67 to 2.26)
Etoricoxib 5-10 mg −0.21 (−0.43 to 0.02) 7.5 0.65 (0.19 to 2.01)
Etoricoxib 30 mg −0.48 (−0.63 to −0.34) 94.3 0.88 (0.58 to 1.33)
Etoricoxib 60 mg* −0.65 (−0.82 to −0.48) 99.9 1.02 (0.62 to 1.68)
Etoricoxib 90 mg −0.84 (−1.09 to −0.59) 100.0 1.58 (0.80 to 3.11)
Ibuprofen 400 mg — — 0.44 (0.09 to 1.46)
Ibuprofen 1200 mg −0.31 (−0.92 to 0.30) 42.1 0.99 (0.39 to 2.53)
Ibuprofen 2400 mg* −0.37 (−0.50 to −0.25) 52.8 1.80 (1.23 to 2.60)
Indomethacin 75 mg −0.30 (−0.74 to 0.14) 37.6 —
Indomethacin 105 mg — — 1.81 (1.05 to 3.20)
Indomethacin 150 mg — — 2.49 (0.74 to 8.49)
Indomethacin 210 mg* — — 3.21 (1.08 to 10.03)
Isoxicam 200 mg† −0.59 (−1.08 to −0.09) 80.6 1.26 (0.58 to 2.69)
Isoxicam 300 mg† — — 5.61 (1.81 to 18.32)
Ketoprofen 200 mg* −0.60 (−1.06 to −0.13) 83.0 0.82 (0.31 to 2.09)
Lornoxicam 16 mg* −0.73 (−1.32 to −0.14) 88.1 —
Lumiracoxib 100 mg −0.33 (−0.52 to −0.13) 33.8 0.88 (0.61 to 1.26)
Lumiracoxib 200 mg* −0.36 (−0.54 to −0.19) 46.1 0.97 (0.66 to 1.41)
Lumiracoxib 400 mg −0.39 (−0.59 to −0.18) 55.9 1.06 (0.71 to 1.57)
Meclofenamate sodium 300 mg −0.31 (−0.88 to 0.25) 41.8 1.82 (0.71 to 4.84)
Meloxicam ≤10 mg −0.33 (−0.52 to −0.13) 33.9 0.97 (0.61 to 1.52)
Meloxicam 15 mg* −0.48 (−0.66 to −0.30) 88.2 1.13 (0.75 to 1.69)
Nabumetone 1000 mg −0.22 (−0.37 to −0.08) 2.3 1.04 (0.68 to 1.59)
Nabumetone 1327 mg — — 1.00 (0.33 to 3.05)
Nabumetone 1500-1831 mg −0.41 (−0.89 to 0.08) 56.3 1.05 (0.73 to 1.51)
Naproxcinod 250 mg 0.04 (−0.21 to 0.29) 0.1 0.63 (0.17 to 1.82)
Naproxcinod 750 mg −0.31 (−0.43 to −0.19) 16.6 1.41 (0.80 to 2.42)
Naproxcinod 1500 mg −0.44 (−0.54 to −0.34) 92.2 1.37 (0.93 to 1.99)
Naproxcinod 2250 mg −0.47 (−0.73 to −0.22) 77.9 —
Naproxen ≤750 mg −0.38 (−0.63 to −0.13) 52.3 1.33 (0.89 to 2.02)
Naproxen 1000 mg* −0.39 (−0.45 to −0.32) 68.1 1.50 (1.24 to 1.83)
Nimesulide 200 mg* −0.35 (−0.65 to −0.06) 45.7 1.29 (0.67 to 2.45)
Nimesulide 800 mg −0.44 (−0.93 to 0.05) 61.0 0.84 (0.28 to 2.32)
Oxaprozin 1200 mg −0.61 (−0.89 to −0.32) 94.6 1.57 (0.89 to 2.74)
Oxaprozin 1800 mg* — — 2.02 (0.80 to 4.87)
Piroxicam 20 mg −0.48 (−0.67 to −0.28) 86.4 1.32 (0.88 to 1.97)
Piroxicam 25.5 mg −0.53 (−1.43 to 0.37) 63.2 2.26 (0.98 to 5.19)
Polmacoxib 2 mg −0.28 (−0.55 to −0.02) 24.9 3.66 (1.28 to 11.99)
Rofecoxib 5 mg† −0.34 (−0.60 to −0.09) 42.2 1.41 (0.44 to 3.93)
Rofecoxib 12.5 mg† −0.41 (−0.49 to −0.33) 86.3 1.22 (0.96 to 1.54)
Rofecoxib 25 mg*† −0.48 (−0.55 to −0.40) 99.6 1.32 (1.04 to 1.68)
Rofecoxib 50 mg† −0.77 (−1.05 to −0.49) 99.8 1.84 (0.54 to 5.35)
Tiaprofenic acid 600 mg* −0.27 (−0.74 to 0.22) 33.5 1.47 (0.84 to 2.63)
Tolfenamic acid 600 mg −0.65 (−1.45 to 0.13) 76.0 1.80 (0.41 to 8.37)
Valdecoxib 5 mg† −0.29 (−0.47 to −0.11) 18.8 1.09 (0.43 to 2.57)
Valdecoxib 10 mg† −0.32 (−0.50 to −0.14) 29.4 1.33 (0.54 to 3.12)
Valdecoxib 20 mg† −0.37 (−0.59 to −0.14) 48.5 —
Zaltoprofen 240 mg* −0.78 (−1.39 to −0.17) 90.7 4.01 (0.29 to 135.37)
Topical
Diclofenac topical 70-81 mg −0.54 (−0.77 to −0.31) 92.3 1.14 (0.74 to 1.72)
Diclofenac topical 140-160 mg −0.61 (−0.87 to −0.35) 96.3 1.58 (0.77 to 3.34)
S-flurbiprofen plaster ≤20 mg −0.25 (−0.92 to 0.42) 36.2 0.40 (0.03 to 4.14)
S-flurbiprofen plaster 40 mg −0.41 (−1.20 to 0.37) 53.9 0.32 (0.01 to 3.82)
Table 2 | Non-steroidal anti-inflammatory drug effect estimates for pain and dropouts due to adverse events compared 
with oral placebo
(Continued)
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and serious adverse events, and table 2 and table 3 
show the results for dropouts due to adverse events. 
Web-appendix 17 displays pooled effect estimates 
for dropouts due to adverse events, ordered by the 
magnitude of harmful effects. Evidence was found, with 
the 95% credible intervals of odds ratios excluding the 
null effect, of an increased number of participants who 
dropped out of the trial due to an adverse event compared 
with placebo for 10 of 54 (18.5%) oral NSAIDs, 0 of 8 
(0%) topical NSAIDs, 15 of 18 (83.3%) opioids, and 1 of 
3 (33.3%) paracetamol interventions. There was strong 
evidence, with the lower bound of the 95% credible 
interval of odds ratios above 2, of an increased number 
of participants who dropped out due to an adverse event 
compared with placebo only for opioid interventions (9 
of 18; 50%). Evidence was found of an increased risk 
of any adverse event for 14 of 47 (29.8%) NSAIDs, 0 of 
9 (0%) topical NSAIDs, 17 of 19 (89.5%) opioids, and 
paracetamol 3900-4000 mg/day. Only oxycodone ≥48 
mg had evidence of an increased risk of serious adverse 
events (odds ratio 2.40, 95% credible interval 1.09 to 
5.60). Oxymorphone 80 mg/day had the highest risk of 
dropouts due to adverse events (51%) and any adverse 
event (88%).
Figure 4 plots the probability of interventions 
having a treatment effect on osteoarthritis pain 
NSAIDs
Pain Dropouts due to adverse 
events, odds ratio (95% Crl)Effect size (95% Crl) Probability of MID
Ibuprofen topical 1500 mg −0.19 (−1.03 to 0.66) 33.7 —
Ketoprofen topical 50 mg −0.15 (−0.64 to 0.33) 18.7 0.67 (0.25 to 1.65)
Ketoprofen topical 100 mg −0.22 (−0.49 to 0.06) 14.1 0.99 (0.44 to 2.15)
Ketoprofen topical 200-220 mg −0.23 (−0.39 to −0.06) 4.4 1.27 (0.79 to 2.02)
Piroxicam topical 15 mg* 0.39 (−0.49 to 1.25) 4.3 1.32 (0.31 to 5.74)
Piroxicam topical 20 mg — — —
CrI=credible interval; MID=between group minimum clinically important difference; NSAID=non-steroidal anti-inflammatory drug.
All treatment effect estimates are comparisons to oral placebo. Number of participants randomised to oral placebo: 18 712. All doses are in mg per 
day. Pain: 84 of 93 interventions or controls included, 170 of 192 trials with available data; dropouts due to adverse events: 86 of 93 interventions or 
controls included, 168 of 192 trials with data available.
*Maximum daily recommended dose.
†Withdrawn from market.
Table 2 | Continued
Table 3 | Opioids, paracetamol, and topical placebo effect estimates for pain and dropouts due to adverse events 
compared with oral placebo
Drugs
Pain Dropouts due to adverse 
events, odds ratio (95% Crl)Effect size (95% Crl) Probability of MID
Opioids
Buprenorphine sublingual 0.87 mg −0.35 (−1.39 to 0.69) 48.7 2.88 (1.19 to 6.88)
Buprenorphine transdermal 0.28-0.36 mg −0.36 (−0.73 to 0.01) 47.9 2.07 (1.19 to 3.61)
Codeine 105-127 mg −0.19 (−0.62 to 0.24) 19.9 1.51 (0.81 to 2.85)
Dextropropoxyphene 300 mg — — 1.02 (0.43 to 2.34)
Fentanyl transdermal 0.6 mg −0.31 (−0.69 to 0.07) 37.6 2.76 (1.22 to 6.32)
Hydromorphone 8 mg −0.01 (−0.53 to 0.50) 8.7 4.93 (2.68 to 9.27)
Hydromorphone 13.9-16 mg −0.16 (−0.51 to 0.18) 12.0 8.72 (5.10 to 15.09)
Hydromorphone 34 mg −0.00 (−0.61 to 0.60) 11.6 —
Morphine with naltrexone 43.5 mg −0.25 (−0.82 to 0.32) 34.1 1.46 (0.62 to 3.52)
Oxycodone ≤40 mg −0.09 (−0.41 to 0.22) 4.5 7.29 (4.83 to 11.17)
Oxycodone ≥48 mg −0.17 (−0.33 to −0.01) 0.9 6.78 (4.70 to 9.66)
Oxymorphone 40 mg −0.23 (−0.77 to 0.30) 31.1 13.26 (6.53 to 27.94)
Oxymorphone 80 mg −0.32 (−0.86 to 0.22) 42.3 19.34 (9.47 to 40.29)
Tapentadol <316 mg −0.34 (−0.50 to −0.17) 33.9 2.58 (1.84 to 3.67)
Tramadol 100-131 mg −0.12 (−0.25 to 0.01) 0.0 1.77 (1.25 to 2.51)
Tramadol 200 mg −0.13 (−0.26 to 0.00) 0.0 2.86 (2.10 to 3.89)
Tramadol 275-300 mg −0.31 (−0.43 to −0.20) 18.1 4.73 (3.52 to 6.39)
Tramadol 400 mg* −0.23 (−0.46 to −0.01) 11.8 4.71 (2.75 to 8.02)
Tramadol with paracetamol 154-225 mg −0.39 (−0.88 to 0.09) 53.0 3.17 (1.55 to 6.84)
Paracetamol
Paracetamol <2000 mg −0.07 (−0.56 to 0.44) 11.8 1.51 (0.58 to 3.72)
Paracetamol 3000 mg −0.21 (−0.81 to 0.39) 29.7 1.31 (0.56 to 3.12)
Paracetamol 3900-4000 mg* −0.15 (−0.25 to −0.05) 0.0 1.35 (1.00 to 1.81)
Placebo
Placebo topical −0.23 (−0.39 to −0.06) 4.6 0.84 (0.55 to 1.27)
Placebo oral and topical 0.07 (−0.22 to 0.35) 0.2 1.20 (0.56 to 2.52)
CrI=credible interval; MID=between group minimum clinically important difference; NSAID=non-steroidal anti-inflammatory drug.
All treatment effect estimates are comparisons to oral placebo. Number of participants randomised to oral placebo: 18 712. All doses are in mg per day. 
The lower bound of the 95% CrI of dropouts due to adverse events for paracetamol 3900-4000 mg is >1, but is shown as 1.00 due to rounding. Pain: 
84 of 93 interventions or controls included, 170 of 192 trials with available data; dropouts due to adverse events: 86 of 93 interventions or controls 
included, 168 of 192 trials with data available.
*Maximum daily recommended dose.
†Withdrawn from market.
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Diclofenac 114-133 mg



















S-flurbiprofen plaster 40 mg
Nabumetone 1500-1831 mg
Diflunisal 1000 mg







Buprenorphine transdermal 0.28-0.36 mg























Dropouts due to adverse events,
odds ratio (95% Crl)
Fig 2 | Treatment effect on osteoarthritis pain and dropouts due to adverse events compared with oral placebo, ordered according to treatment effect 
size on osteoarthritis pain. Blue: oral non-steroidal anti-inflammatory drugs; green: topical non-steroidal anti-inflammatory drugs; orange: opioids. 
Area between dashed lines shows treatment effect estimates below the minimum clinically important difference. See web-appendix 17 for caterpillar 
plot ordered according to odds ratio of dropouts due to adverse events. See table 2, table 3, and web-appendix 7 for specific estimates with 95% CrI 
and additional outcome. *Maximum daily recommended dose. CrI=credible interval
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beyond the MID against the probability of participants 
dropping out due to an adverse event. The plot shows 
that some oral and topical NSAID interventions had 
>90% probability of having a treatment effect beyond 
the MID while still having a probability of participants 
dropping out similar to that observed with oral 
placebo (5%). The plot also shows that participants 
who received opioids tended to have a much lower 
probability of experiencing a clinically relevant 
reduction in their pain compared with oral placebo, 
but a much higher risk of interrupting treatment due 
to an adverse event.
Model fit, heterogeneity, and inconsistency 
assessment
The model fit was good for all outcomes (web-
appendix 18 and 19). τ2 estimates suggest low 
statistical heterogeneity for all outcomes, except for 
serious adverse events, which had a small to moderate 
statistical heterogeneity49: pain (0.010, 95% credible 
Tramadol 275-300 mg
Meclofenamate sodium 300 mg
Ibuprofen 1200 mg





Tiaprofenic acid 600 mg*
S-flurbiprofen plaster ≤20 mg




Ketoprofen topical 200-220 mg
Nabumetone 1000 mg
Ketoprofen topical 100 mg
Paracetamol 3000 mg
Etoricoxib 5-10 mg














Placebo oral and topical
Piroxicam topical 15 mg*












Dropouts due to adverse events,
odds ratio (95% Crl)
Fig 3 | Continuation of figure 2. Treatment effect on osteoarthritis pain and dropouts due to adverse events compared with oral placebo, ordered 
according to treatment effect size on osteoarthritis pain. Blue: oral non-steroidal anti-inflammatory drugs; green: topical non-steroidal anti-
inflammatory drugs; orange: opioids; pink: paracetamol; black: placebo. Area between dashed lines shows treatment effect estimates below the 
minimum clinically important difference. See web-appendix 17 for caterpillar plot ordered according to odds ratio of dropouts due to adverse 
events. See table 2, table 3, and web-appendix 7 for specific estimates with 95% CrI and additional outcome. *Maximum daily recommended dose. 
CrI=credible interval
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interval 0.007 to 0.015), physical function (0.010, 
0.006 to 0.015), dropouts due to adverse events (0.046, 
0.006 to 0.097), any adverse event (0.026, 0.010 to 
0.049), and serious adverse events (0.118, 0.001 to 
0.498). For all outcomes, the deviance information 
criterion was better in the consistency model than in 
the inconsistency model (web-appendix 20).
Discussion
Main findings
This network meta-analysis, including 192 trials and 
102 829 participants, compared the effectiveness and 
safety of 90 active treatment regimens of NSAIDs, 
opioids, and paracetamol with oral placebo. Diclofenac 
150 mg/day and etoricoxib 60 mg/day appear to be the 
most effective interventions to improve pain in patients 
with knee or hip osteoarthritis. Diclofenac 150 mg/day 
had an effect size of −0.56 and etoricoxib 60 mg/day 
had an effect size of −0.65, corresponding to 14 mm 
and 16 mm differences on a 100 mm visual analogue 
scale, respectively; these figures are 1.5 and 1.8 times 
the between group MID for chronic pain of an effect 
size of −0.37. There was 99.9% probability that these 
interventions have treatment effects that are more 
pronounced than the between group MID. While these 
two interventions showed similar increased risks of any 
adverse event compared with placebo (odds ratio 1.27 
and 1.56, respectively), patients receiving etoricoxib 
60 mg/day seemed to have a lower risk of stopping the 
treatment due to an adverse event. Etoricoxib 60 mg/
day also seemed to result in a lower risk of patients 
experiencing a serious adverse event than diclofenac 
150 mg/day, but effect estimates were imprecise.
Among topical treatments, diclofenac, regardless 
of dose, had the largest effect on pain and physical 
function. The lowest dose of topical diclofenac (70-81 
mg/day) had a 92% probability of having a minimum 
clinically relevant improvement on pain, with a better 
safety profile than oral diclofenac. Among the NSAID 
preparations most commonly prescribed in the US, 
meloxicam and diclofenac were more effective and had 
similar safety outcomes compared with ibuprofen and 
naproxen at their respective maximum recommended 
daily doses.50 While none of the opioid interventions, 
regardless of dose, seemed to have a clinically relevant 
effect on pain or physical function, their safety profiles 
were in general significantly worse than the other 
interventions in our analysis, with higher doses of 
opioids leading to a higher risk of harm. Tramadol, 
regardless of dose, had a small treatment effect on 
pain and physical function (effect sizes ≥−0.31; 
probabilities to reach the MID ≤18.1%). Among non-
tramadol opioids, tapentadol seemed to be the most 
effective in treating pain (effect size −0.34; probability 
to reach the MID 33.9%). Paracetamol 3900-4000 
mg/day had the lowest effect on osteoarthritis pain, 
with an effect size of −0.15, corresponding to a 4 mm 
difference on a 100 mm visual analogue scale, similar 
to previously reported results.33
Strengths and limitations
This was a large network meta-analysis on 
pharmacological treatments for knee and hip 
osteoarthritis. Even after restricting our inclusion 
criteria to large trials only, our sensitive search strategy 
and careful search of the grey literature resulted in 
a 2.5-fold to fivefold increase in the number of trials 
and patients included compared with previous reviews 
specific to NSAIDs, opioids, or paracetamol (web-
appendix 3). The large number of trials and patients 
included allowed us to generate granular evidence 
of effectiveness and safety with enough statistical 
precision for several different types of interventions 
and doses. By excluding trials with small sample sizes, 
we minimised the risk of biases caused by small study 
effects.29 Web-appendix 12 shows that trials included 
in our analyses generally had a lower risk of bias, which 
is reassuring. Additionally, conclusions based on our 
analyses adjusted by risk of biases were in line with the 
unadjusted analysis. The robustness and accuracy of 
our results are further supported by the low between 
trial heterogeneity, no indication of inconsistency in 
the network, good model fit, and similar treatment 
effects for pain and function. The length of follow-up 
in about half of the included trials was three months 
or less, which we believe is an accurate representation 
of current clinical practice, and is in line with current 
clinical practice guidelines.6 7 Treatment effect 
estimates were consistent for one, six, and 12 weeks of 
follow-up, which is further evidence of the robustness 
of our findings and of the effectiveness of these drugs 
from short to mid-term use.
The risk of harm of the oral treatments we analysed 
is well established, therefore they are typically 
prescribed on an as-needed basis, with intermittent 
short to mid-term use and varying doses as required, 
rather than a daily fixed dose treatment regimen as 
seen in the trials included in our analysis. Because 
the average treatment duration in included trials 
was less than three months, our findings for safety 
outcomes should not be generalised to long term use 
of the interventions considered in our analysis because 
harmful effects probably become more frequent and 
































Fig 4 | Two-dimensional graph showing probability of drugs having minimum clinically 
important difference compared with oral placebo and probability of participants 
interrupting treatment due to adverse event. Probability of participants on oral placebo 
dropping out due to adverse event is 5%. MID=between group minimum clinically 
important difference; NSAID=non-steroidal anti-inflammatory drug
 on 19 O












J: first published as 10.1136/bm






12 doi: 10.1136/bmj.n2321 | BMJ 2021;375:n2321 | the bmj
severe as treatment duration increases. Current trials 
do not allow a proper exploration of the effectiveness 
and safety of NSAIDs in the presence of comorbidities, 
which requires careful consideration when using 
our findings to guide clinical practice. Patients with 
comorbidities that lead to a higher risk of adverse 
events are underrepresented in the trials included in 
our analysis. Therefore, the safety estimates from our 
analyses are mainly generalisable to patients with 
a lower risk of experiencing adverse events, and are 
probably conservative estimates for frail patients 
with multimorbidities. Future pragmatic trials that 
investigate the longer term use of NSAIDs on an as-
needed basis and varying doses as required in patients 
with osteoarthritis and comorbidities, and that report 
cause specific adverse events, will enable safer use of 
these drugs in this patient group.
Data on cause specific adverse events, such as 
gastrointestinal and cardiovascular, are helpful 
to physicians and patients in the presence of 
comorbidities. A proper comparison of cause specific 
adverse events for different types of drugs in a network 
meta-analysis would require drug doses to be taken 
into account. Only a small proportion of the trials 
reported cause specific adverse events, therefore 
analysis at the level of preparation and doses was 
not possible in the present network meta-analysis. It 
is conceivable that different types of topical NSAID 
formulations (eg, patch, cream, gel) might have 
different effectiveness and safety profiles. The current 
analysis did not include enough trials to explore this 
potential effect modification with adequate statistical 
precision. As new evidence from large trials becomes 
available, a future network meta-analysis on topical 
NSAIDs could explore potential effect modification of 
their effectiveness and safety according to different 
types of formulations.
The risk of performance bias introduced by therapists 
was unclear for some trials, and most trials had a high 
risk of incomplete outcome bias because they used last 
observation carried forward to account for missing data. 
However, conclusions based on our analyses adjusted 
by risk of biases were in line with the unadjusted 
analysis.29 We must recognise the limitations of our 
analysis model, as previously discussed.33 Because 
study specific covariance estimates are rarely reported, 
the dependency of outcome data over time within a 
trial is only approximately represented through the 
random walk. Additionally, if a strong temporal pattern 
such as a linear trend exists, our random walk model 
cannot properly account for it. Although most of the 
estimates presented have enough statistical precision 
to allow sound conclusions about the effectiveness 
and safety of interventions, some estimates have wide 
95% credible intervals, especially for serious adverse 
events.
Previous evidence
This network meta-analysis compares the effectiveness 
and safety of different doses and preparations of oral 
and topical NSAIDs, opioids, and paracetamol in a 
single analysis. We previously published a similar 
network meta-analysis that assessed the effectiveness 
of oral NSAIDs and paracetamol.33 With the ever 
increasing use of opioids in osteoarthritis treatment 
and the recommendation from recent guidelines to 
consider topical NSAIDs as a first line treatment, we 
expanded the previous review to also include these 
interventions to assess their comparative effectiveness 
and safety.6-9 16 18 We also included safety outcomes 
in the current review, which were not reported in our 
previous review. Recent guidelines suggest that when 
these interventions are used, the lowest possible dose 
should be prescribed to minimise the risk of adverse 
events.6 7 Safety outcomes presented alongside 
effectiveness outcomes allow physicians, patients, 
or their caregivers to have a better understanding of 
which preparations at their lowest doses would be 
safest while still being effective. Finally, the current 
review, with a literature search conducted in June 2021, 
provides an update of the evidence on the effectiveness 
of oral NSAIDs reported in our last review, which had a 
literature search conducted in February 2015.
The findings of our current and previous analyses 
indicate that diclofenac 150 mg/day and etoricoxib 
60 mg/day seem to be the most effective NSAIDs for 
osteoarthritis pain. Previous studies indicate that 
etoricoxib has a similar risk to placebo and a lower 
risk than diclofenac of causing gastrointestinal 
adverse events, but a higher risk than placebo and a 
similar risk to diclofenac of cardiovascular adverse 
events.51-53 Our dose specific analysis indicates that 
etoricoxib 60 mg/day, compared with diclofenac 150 
mg/day, would lead to fewer people dropping out due 
to adverse events, a similar risk of any adverse events, 
and possibly a lower risk of serious adverse events. 
However, etoricoxib is not approved in the US where the 
FDA requires additional safety and efficacy data before 
deciding on its approval. In 2007, the FDA arthritis 
advisory committee voted 20 to 1 against the approval 
of etoricoxib given concerns about the drug’s increased 
risk of cardiovascular events and its association with 
worsening of hypertension.54 Data taken into account 
for this decision considered a possibly sixfold increase 
in the risk of cardiovascular events with etoricoxib 
compared with naproxen,54 which was not confirmed 
by a later network meta-analysis examining the 
cardiovascular safety of NSAIDs.51
Our findings suggest that rofecoxib 25 mg/
day, a drug removed from the market because of 
cardiovascular safety concerns, is as effective as 
diclofenac and etoricoxib and with a similar safety 
profile, as corroborated by previous studies.33 51 The 
cardiovascular safety of rofecoxib was first questioned 
by the VIGOR trial in 2000, which reported a significant 
increase in the risk of myocardial infarction in patients 
who received this drug compared with those who 
received naproxen.55 However, rofecoxib was only 
removed from the market in 2004. This decision was 
mainly based on the three year results of the APPROVe 
trial, which was a placebo controlled trial of rofecoxib 
for the prevention of recurrence of colorectal polyps in 
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patients with a history of colorectal adenomas.56 57 In 
this trial, patients were randomly allocated to receive 
one 25 mg tablet of rofecoxib each day (the maximum 
recommended long term daily dose) or a placebo 
tablet each day for three years. The results indicated 
an increased cardiovascular risk with long term (>18 
months), fixed dose, daily use of rofecoxib.56 57 No 
evidence was found of an increased cardiovascular risk 
in the first 18 months of use, but patients with a history 
of cardiovascular disease were not included in this trial.
Recent network meta-analyses have suggested that 
topical NSAIDs could be beneficial for osteoarthritis 
treatment.28 58 However, these analyses included 
observational studies and small trials of low 
methodological quality, or did not provide treatment 
effect estimates separately for each drug preparation 
and dose. Our findings are based on high quality 
randomised trials and indicate that topical diclofenac 
70-81 mg/day might be the best treatment in terms of 
effectiveness and safety. However, all diclofenac topical 
trials included only patients with knee osteoarthritis, 
so the evidence is unclear for hip osteoarthritis. Patients 
with osteoarthritis who require analgesic treatment 
but have not responded to first line treatments, such 
as topical NSAIDs, and have a contraindication to oral 
NSAIDs, might be prescribed opioids or paracetamol.6 
Recent reviews indicate that both treatments do not 
have a clinically relevant effect on osteoarthritis 
symptoms and also raised safety concerns.11 33 34 59 Our 
analyses indicate that the small benefits of opioids or 
paracetamol might be outweighed by potential harms, 
regardless of dose. However, our findings are based on 
average estimates and it is possible that some of the 
patients who did not respond to other treatments could 
still benefit from opioids or paracetamol.60 61 We have 
previously shown that no association exists between 
opioid dose and improvement in osteoarthritis pain.34 
The findings of the current analysis corroborate this 
finding and also indicate that higher doses of opioids 
lead to more harm.
Implications for clinical practice
Physicians could use the results of our analysis to 
identify the lowest doses of different drug preparations 
that are effective and safe when first prescribing 
treatment, as generally recommended by current 
clinical practice guidelines.6 7 Treatment should 
preferably be on an as-needed basis, with intermittent 
short to mid-term use and varying doses as required, 
instead of a long term daily fixed dose. Our results 
indicate that lower doses of oral NSAIDs, such as 
oral diclofenac 100-105 mg/day and etoricoxib 30 
mg/day, or topical diclofenac 70-81 mg/day, have 
more favourable safety profiles than maximum 
recommended daily doses, while still having >88% 
probability of treatment effects more pronounced than 
the MID. The potential benefits of these interventions 
must be carefully weighed against potential harms 
for each individual patient because the presence 
of comorbidities or long term use might increase 
the risk of serious adverse events.6 7 51 62 For knee 
osteoarthritis, topical treatments are recommended 
before oral treatments because of their lower 
systemic exposure or toxicity.6 7 The 2019 guidelines 
of the Osteoarthritis Research Society International 
recommend topical NSAIDs for patients with knee 
osteoarthritis and gastrointestinal or cardiovascular 
comorbidities, or those who are frail because adverse 
events are minimal and mild; most are minor and 
transient local skin reactions.7 No recommendation 
was made for the use of topical NSAIDs in hip 
osteoarthritis, considering that the depth of the hip 
joint would make it unlikely for a benefit to occur. 
None of the trials included in our analysis investigated 
topical NSAIDs in patients with hip osteoarthritis. Oral 
NSAIDs received a conditional recommendation for 
knee and hip osteoarthritis without comorbidities, 
with cyclooxygenase 2 inhibitors recommended in the 
presence of gastrointestinal comorbidities.
Our findings indicate that opioids and paracetamol 
have a significantly smaller effect on knee or hip 
osteoarthritis pain and physical function, with 
an increased risk of harm associated with opioids 
and paracetamol compared with oral and topical 
NSAIDs. The evidence also indicates that the low 
effect of opioids on pain and physical function do 
not outweigh the harm they might cause in patients 
with osteoarthritis. The 2019 American College 
of Rheumatology/Arthritis Foundation guidelines 
conditionally recommended paracetamol and 
tramadol for patients with contraindications to oral 
NSAIDs or those who did not respond to previous 
treatment.6 Non-tramadol opioids were conditionally 
not recommended, however the guidelines recognise 
that they could be helpful at the lowest possible dose 
and for the shortest possible treatment duration in 
some patients for whom conservative alternatives 
have been exhausted. Our findings show that even 
when patients receive lower doses of non-tramadol 
opioids, they are up to 13 times more likely to interrupt 
treatment due to adverse events, and up to 10 times 
more likely to experience any type of adverse events 
compared with oral placebo.
Conclusions
Etoricoxib 60 mg/day and diclofenac 150 mg/day seem 
to be the most effective oral NSAIDs for osteoarthritis 
pain, but are probably not appropriate in the presence 
of comorbidities or for long term daily use given the 
mild increase in the risk of adverse events for both 
drugs. Additionally, an increased risk of dropping out 
due to adverse events was found for diclofenac 150 
mg/day. Topical diclofenac 70-81 mg/day could be 
effective and safer due to reduced systemic exposure 
and lower dose, and should be considered as a first 
line pharmacological treatment for knee osteoarthritis. 
The clinical benefit of opioid treatment, regardless of 
preparation or dose, does not outweigh the harm it 
could cause in patients with osteoarthritis.
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